Background Hyperphosphatemia is associated with increased fibroblast growth factor 23
(FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering
medication on vascular calcification and arterial stiffness in CKD remain uncertain. Methods
To assess the effects of non–calcium-based phosphate binders on intermediate
cardiovascular markers, we conducted a multicenter, double-blind trial, randomizing 278
participants with stage 3b or 4 CKD and serum phosphate> 1.00 mmol/L (3.10 mg/dl) to 500 …